The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies
Description
<jats:title>Abstract</jats:title> <jats:p>T-cell activation and dysfunction relies on direct and modulated receptors. Based on their functional outcome, co-signaling molecules can be divided as co-stimulators and co-inhibitors, which positively and negatively control the priming, growth, differentiation and functional maturation of a T-cell response. We are beginning to understand the power of co-inhibitors in the context of lymphocyte homeostasis and the pathogenesis of leukemia, which involves several newly described co-inhibitory pathways, including the programmed death-1 (PD-1) and PD-1 ligand (PD-L1) pathway. The aim of this review is to summarize the PD-1 and PD-L1 biological functions and their alterative expression in hematological malignancies. The role of PD-1 and PD-L1 in T-cell immune suppression and the potential for immunotherapy via blocking PD-1 and PD-L1 in hematological malignancies are also reviewed.</jats:p>
Journal
-
- Journal of Hematology & Oncology
-
Journal of Hematology & Oncology 6 (1), 74-, 2013-09-30
Springer Science and Business Media LLC
- Tweet
Details 詳細情報について
-
- CRID
- 1361418520317765376
-
- ISSN
- 17568722
-
- Data Source
-
- Crossref